Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing
Current Problems in Cancer: Case Reports · 2020
DOI: 10.1016/j.cpccr.2020.100008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Problems in Cancer: Case Reports, 2020. Verfasst von Uwe Güth und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pleomorphic lobular carcinoma (PLC) of the breast with osteoclast like giant cells (OGC) is a very rare variant of lobular carcinoma associated with tumour-associated macrophages (TAM) in the microenvironment. High content of TAM in breast cancer is associated with poor survival rates. Using genomic testing for the individual risk assessment in breast cancers with special features of their microenvironment might be skewed by the fact, that most recommended tests investigate proliferation and oestrogen receptor associated genes of tumour cells in their risk stratification but do not take into consideration the microenvironment. So far, no disease-specific molecular alteration could be identified in NST and lobular invasive carcinoma with OGC.
Zitieren
APA
Güth, U., Borovecki, A., Amann, E., Rechsteiner, M., & Tinguely, M. (2020). Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing. Current Problems in Cancer: Case Reports. https://doi.org/10.1016/j.cpccr.2020.100008
Vancouver
Güth U, Borovecki A, Amann E, Rechsteiner M, Tinguely M. Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing. Current Problems in Cancer: Case Reports. 2020. doi:10.1016/j.cpccr.2020.100008
BibTeX
@article{Gth2020,
author = {Güth, Uwe and Borovecki, Ana and Amann, Esther and Rechsteiner, Markus and Tinguely, Marianne},
title = {Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing},
journal = {Current Problems in Cancer: Case Reports},
year = {2020},
doi = {10.1016/j.cpccr.2020.100008}
}
EUVIMED